Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator
- PMID: 1607530
- DOI: 10.1016/0735-1097(92)90164-i
Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator
Abstract
Coronary artery reocclusion after thrombolysis with human recombinant tissue-type plasminogen activator (rt-PA) is related to the short half-life of this agent in plasma. K2P, a mutant of rt-PA lacking the fibronectin fingerlike, epidermal growth factor-like and first kringle domains (amino acids 6 to 173) and having the glycosylation site Asn184 mutagenized to Gln, has been produced in Chinese hamster ovary cells. In this study we compared the thrombolytic effect of K2P and rt-PA in dogs with electrically induced coronary artery thrombosis. Both agents were given intravenously in equimolar amounts over 20 min after the occlusive thrombus was stable for 30 min; dogs were monitored for 1 h after reperfusion if flow occurred. Coronary blood flow was restored by rt-PA in 6 (60%) of 10 dogs. The restored flow lasted for 49 +/- 12 min and mean flow at 60 min from the start of reperfusion was 7 +/- 3 ml/min. The reocclusion rate was 50% (three of six dogs). Flow was restored in five (100%) of five dogs by K2P. The restored blood flow lasted during the entire 1-h observation period in all but one dog and mean flow at 60 min was 49 +/- 16 ml/min (p less than 0.02 vs. flow in rt-PA-treated dogs). Restored coronary blood flow showed marked cyclic flow variations in rt-PA-treated but not in K2P-treated dogs.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.J Cardiovasc Pharmacol. 1990 Jul;16(1):112-20. doi: 10.1097/00005344-199007000-00016. J Cardiovasc Pharmacol. 1990. PMID: 1696653
-
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.Cardiovasc Res. 1991 Apr;25(4):283-9. doi: 10.1093/cvr/25.4.283. Cardiovasc Res. 1991. PMID: 1909212
-
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model.J Cardiovasc Pharmacol. 1990 Aug;16(2):197-203. doi: 10.1097/00005344-199008000-00004. J Cardiovasc Pharmacol. 1990. PMID: 1697374
-
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.J Am Coll Cardiol. 1990 Dec;16(7):1728-35. doi: 10.1016/0735-1097(90)90327-l. J Am Coll Cardiol. 1990. PMID: 2123910
-
Circadian variations in cardiovascular disease.Cleve Clin J Med. 1989 Oct;56(7):676-80. doi: 10.3949/ccjm.56.7.676. Cleve Clin J Med. 1989. PMID: 2688990 Review.
Cited by
-
Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.J Thromb Thrombolysis. 2001 May;11(3):195-202. doi: 10.1023/a:1011952602122. J Thromb Thrombolysis. 2001. PMID: 11577257 Review.
-
Streptokinase--the drug of choice for thrombolytic therapy.J Thromb Thrombolysis. 2007 Feb;23(1):9-23. doi: 10.1007/s11239-006-9011-x. J Thromb Thrombolysis. 2007. PMID: 17111203 Review.
-
2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.J Vet Emerg Crit Care (San Antonio). 2022 Jul;32(4):446-470. doi: 10.1111/vec.13227. J Vet Emerg Crit Care (San Antonio). 2022. PMID: 35881647 Free PMC article.
-
Effects of Recombinant Human Megakaryocyte Growth and Development Factor (rHuMGDF) on Platelet Production, Platelet Aggregation, and Thrombosis.J Thromb Thrombolysis. 1998;5(1):15-23. doi: 10.1023/a:1008811813115. J Thromb Thrombolysis. 1998. PMID: 10608045
-
Evaluation of thrombolytic potential of three medicinal plants available in Bangladesh, as a potent source of thrombolytic compounds.Avicenna J Phytomed. 2014 Nov;4(6):430-6. Avicenna J Phytomed. 2014. PMID: 25386407 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources